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T-kininogen is known to be an acute-phase reactant as well as a kininogen in rat plasma. Three kinds of cytokines, inter- 
leukin-1, tumor necrosis factor and interferon, were assayed for their abilities to stimulate hepatic production of T-kinino- 
gen. Of these cytokines, interferon was able to stimulate hepatic production of T-kininogen, but few effects were observed 
for interleukin-1 and tumor necrosis factor. In addition, the stimulatory effect of interferon was inhibited by tumor necro- 
sis factor. Our data suggest hat interferon is a candidate for the leukocyte-derived factor mediating the acute-phase re- 
sponse of T-kininogen. 
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1. INTRODUCTION 
Tissue injury caused by chemical agents, 
bacterial infections, rheumatoid arthritis, tissue in- 
farction and neoplasia results in biochemical and 
physiological changes known as the acute-phase 
response [1,2]. One of these changes includes 
elevated levels of plasma proteins designated 
acute-phase reactants [3]. It has been found that 
activated monocytes, tissue macrophages and 
keratinocytes synthesize and release factors 
responsible for stimulating the hepatic production 
of acute-phase reactants [4-61. Some of these fac- 
tors have been identified to be IL-l, TNF and HSF 
171. 
Rat plasma contains a unique kininogen, T- 
kininogen, which releases isoleucyl-seryl- 
bradykinin (T-kinin) upon trypsinization 181. T- 
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kininogen has also been identified as an acute- 
phase reactant [9,10] and has subsequently been 
demonstrated to be a cysteine proteinase inhibitor 
present in rat plasma [l 11. In the previous study, 
we demonstrated that macrophages collected from 
rats receiving inflammatory stimuli triggered T- 
kininogen production in vivo and in vitro [12]. In 
order to identify the macrophage-derived factor(s) 
responsible for stimulating the hepatic production 
of T-kininogen, we have investigated the in vitro 
and in vivo effects of IL-l, TNF and IFN in rats. 
2. MATERIALS AND METHODS 
2.1. Materials 
Recombinant human IL-1~ (2 x 10’ units/mg protein) and 
TNF (3 x lo6 umts/mg protein) were kindly supplied by Dainip- 
pon Pharmaceutical Co., Ltd (Osaka, Japan). Rat IFN (1.9 x 
IO6 units/mg protein) and antibody against rat IFN were pur- 
chased from Lee Biomolecular Research Laboratories, Inc. 
(San Diego, CA). 
2.2. In vivo weriments 
Rat hepatocytes were prepared from male Fisher-344 rats as 
described [12], and the cells (1.8 x ld) were plated in 24-well 
culture plates in 1 ml of William’s E medium supplemented 
with insulin (1 x lo-’ M), dexamethasone (1 x lo-’ M), gen- 
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tamicin (50 pg/ml) and fetal calf serum (5%) (basal medium) at 
37°C in 5% COZ-95% air, as described [12]. Following culture 
for 48 h, the medium was changed to 0.5 ml of fresh medium 
containing one of several concentrations of IL-l, TNF or IFN. 
48 h after culture, the medium was collected and subjected to 
T-kininogen radioimmunoassay as described in [ 131. Amounts 
of rat albumin secreted from hepatocytes were also determined 
by radioimmunoassay using I*’ I- labeled rat albumin and rabbit 
antiserum for rat albumin. 
2.3. In vivo experiments 
IL-1 (2 x 104 units), TNF (5 x 104 units) and IFN (500 units), 
made up in saline, were injected intraperitoneally into male 
Fisher-344 rats, weighing 100-120 g. Immediately before and at 
different times after the treatments, the tail-tip of each animal 
was cut with a razor and 100 81 of blood was collected into an 
EDTA-treated capillary tube. The tube was centrifuged and the 
plasma obtained was subjected to T-kininogen radioim- 
munoassay. 
2.4. Statistical analysis 
Data were expressed as the mean f SD of 4 experiments. 
Statistical analysis was carried out using Student’s t-test. 
3. RESULTS 
Fig. 1 shows effects of human IL-l, TNF and rat 
IFN on the amount of T-kininogen secreted from 
cultured rat hepatocytes. IL-l had no effect on T- 
kininogen secretion at concentrations up to 10000 
units/ml, but TNF caused a slight increase in T- 
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Fig.1. Effects of interleukin-1, tumor necrosis factor and 
interferon on the secretion of T-kininogen from cultured 
hepatocytes. Rat hepatocytes were cultured in 0.5 ml of basal 
medium supplemented with one of several concentrations of 
human interleukin-1 (q ), human tumor necrosis factor (A) and 
rat interferon (0) for 48 h, and then the secreted amounts of 
T-kininogen were assayed. Significantly different from basal 
secretion: *p < 0.05, **p < 0.001. 
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Fig.2. Effects of intraperitoneal administration of 
interleukin-1, tumor necrosis factor and interferon on plasma 
level of T-kininogen. Following i.p. administration of human 
interleukin-1 (2 x lo4 units; n ) and tumor necrosis factor (5 x 
10“ units: A) and rat interferon (500 units; l ), plasma was 
collected at different times and T-kininogen concentration was 
assayed. Significantly different from control (0 h): *p < 0.05, 
**p < 0.001. 
kininogen secretion at high concentrations (10000 
units/ml). IFN exhibited dose-dependent stimula- 
tion of T-kininogen secretion in the range from 16 
to 500 units/ml. The stimulatory activity of IFN 
was neutralized by an antibody against rat IFN 
“r 
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Fig.3. Effects of interleukin-1 and tumor necrosis factor on 
interferon-induced stimulation of T-kininogen secretion from 
cultured hepatocytes. Rat hepatocytes were cultured for 48 h in 
the presence or absence of rat interferon (50 units/ml) with one 
of several concentrations of human interleukin-1 or tumor 
necrosis factor. (0) Non-addition; (0) interferon alone; (0) 
interleukin-1 alone; (A) tumor necrosis factor alone; (m) 
interferon plus interleukin-1; (A) interferon plus tumor necrosis 
factor. * Significantly different @ < 0.001) from interferon 
alone. ** Significantly different @ < 0.05) from non-addition. 
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(not shown). At the maximum response, T- 
kininogen secretion was increased approx. IO-fold 
over the basal secretion. On the other hand, 
neither cytokine affected the secretion of albumin 
at concentrations used in this study (not shown). 
In order to ascertain the effect of IFN in vivo, 
two monokines and IFN were injected into rats, 
and plasma T-kininogen levels were measured. As 
shown in fig.2, IFN caused a significant elevation 
of the plasma T-kininogen level, and an approx. 
4-fold elevation was observed at 48 h. On the other 
hand, IL-l had no effect and TNF caused a slight 
elevation of the plasma T-kininogen level. 
Since synergism between TNF and IFN has been 
reported with regard to their cytostatic or cytotoxic 
effect [14-161, it was examined in vitro whether 
the stimulatory effect of IFN on hepatic produc- 
tion of T-kininogen was modified by the presence 
of TNF or IL-l. As shown in fig.3, the IFN- 
induced increase of T-kininogen secretion from 
hepatocytes was inhibited by the presence of TNF 
in a dose-dependent manner. However, IL-l did 
not affect the IFN-induced stimulation. 
4. DISCUSSION 
In the present study, we demonstrated that IFN 
had the ability to stimulate the hepatic production 
of T-kininogen. Three kinds of monokines, i.e., 
IL-l, TNF and HSF, have been identified to be 
mediators responsible for the induction of acute- 
phase reactants. Recently, Baumann et al. [7] 
demonstrated the existence of at least two types of 
HSF and showed that a combination of the two 
HSFs had the ability to induce overall acute-phase 
reactants, while the abilities of IL-l and TNF were 
limited to only a few sets of acute-phase reactants. 
In addition, it was recently reported that human B- 
cell stimulatory factor 2, which was identical to 
IFN-flu, had the ability to increase or decrease the 
hepatic mRNA level of fibrinogen or albumin, 
respectively [17]. From evidence that an antibody 
against B-cell stimulatory factor 2 inhibited this 
stimulatory activity in monocyte-conditioned 
medium, the authors suggested that B-cell 
stimulatory factor 2 or IFN-,& were identical to 
HSF [ 171. These findings suggest a possibility that 
IFN-& which is possibly identical to HSF, in the 
preparation of rat IFN used in this study, is a fac- 
tor responsible for stimulating the hepatic produc- 
tion of T-kininogen. However, in the present 
study, albumin secretion from hepatocytes was not 
affected by rat IFN suggesting that IFN& in the 
preparation of rat IFN may not be responsible for 
the stimulatory effect of T-kininogen production. 
Since, in addition to the species pecificity of IFN, 
rat IFN has not been extensively investigated, it is 
difficult to identify the kind if IFN which is 
responsible for the induction of T-kininogen. 
IFN has been shown to promote the cytostatic or 
cytotoxic activity of TNF in different types of 
transformed cells [14-161. In contrast to the 
cytotoxic synergism between IFN and TNF, the 
stimulatory activity of IFN on the hepatic produc- 
tion of T-kininogen was inhibited by TNF. A 
similar antagonism has been reported in the 
growth of fibroblasts, in which the stimulatory ac- 
tivity of TNF was inhibited by IFN [18]. The 
mechanism responsible for the inhibition of 
hepatic production of T-kininogen by TNF re- 
mains to be elucidated. 
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